Evaluation of patient expectations and treatment satisfaction after 1-year Tadalafil therapy for erectile dysfunction: The DETECT study

Journal of Sexual Medicine

Volumn 6, Issue 1, 2009, Pages 257-267

  Perimenis, Petros ^a   Roumeguere, Thierry ^b   Heidler, Helmut ^c   Roos, Erik ^d   Belger, Mark ^e   Schmitt, Henry ^f  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b ERASME HOSPITAL   (Belgium)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e ELI LILLY AND COMPANY   (United States)

^f Eli Lilly Benelux   (Belgium)

Author keywords

Erectile dysfunction; Expectations; Phosphodiesterase 5 inhibitors; Satisfaction; Tadalafil

Indexed keywords

TADALAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EXPECTATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; SCORING SYSTEM; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; TREATMENT DURATION;

EID: 58149523186     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01027.x     Document Type: Article

References (40)

1. Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott JA. Sexuality after treatment for early prostate cancer: Exploring the meanings of "erectile dysfunction". J Gen Intern Med 2001;16:649-55.
2. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998;52:848-52.
3. Fugl-Meyer AR, Lodnert G, Branholm I-B, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-8.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
5. Althof SE. Quality of life and erectile dysfunction. Urology 2002;59:803-10.
6. Rosen RC, Seidman SN, Menza MA, Shabsigh R, Roose SP, Tseng LJ, Orazem J, Siegel RL. Quality of life, mood, and sexual function: A path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004;16:334-40.
7. Litwin MS, Nied RJ, Dhanani N. Health-related quality of life in men with erectile dysfunction. J Gen Intern Med 1998;13:159-66.
8. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
9. Nicolosi A, Moreira ED Jr, Villa M, Glasser DB. A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J Affect Disord 2004;82:235-43.
10. Briganti A, Salonia A, Deho F, Zanni G, Barbieri L, Rigatti P, Montorsi F. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. World J Urol 2005;23:374-84.
11. Gil A, Martinez E, Oyaguez I, Palacios G, Rejas J. Erectile dysfunction in a primary care setting: Results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001;13:338-47.
12. Gonzalgo ML, Brotzman M, Trock BJ, Geringer AM, Burnett AL, Jarow JP. Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003;170:503-6.
13. Souverein PC, Egberts ACG, Meuleman EJH, Urquhart J, Leufkens HGM. Incidence and determinants of sildenafil (dis)continuation: The Dutch cohort of sildenafil users. Int J Impot Res 2002;14:259-65.
14. Heaton JPW, Hackett G, Savage D, Padley RJ. Patient choice is critical in managing erectile dysfunction. Eur Urol Suppl 2002;1:33-7.
15. Hatzimouratidis K, Hatzichristou DG. Treatment options for erectile dysfunction in patients failing oral drug therapy. EAU Update Ser 2004;2:75-83.
16. Althof SE. When an erection alone is not enough: Biopsychosocial obstacles to lovemaking. Int J Impot Res 2002;14:S99-S104.
17. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998;159:1541-7.
18. Roumeguere T, Verheyden B, Arver S, Bitton A, Belger M, Schmitt H. Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: Results from the DETECT study. J Sex Med 2008;5:1708-19.
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
20. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, Stecher V, Seftel A. EDITS Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999;53:793-9.
21. Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 2005;65:353-9.
22. DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:147-53.
23. Lewis R, Bennett CJ, Borkon WD, Boykin WH, Althof SE, Stecher VJ, Siegel RL. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 2001;57:960-5.
24. McCullough AR, Carson CC, Hatzichristou D. A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra [registered trademark]) for erectile dysfunction. Urology 2006;68:38-46.
25. NIH Consensus Development Panel on Impotence. NIH consensus conference. Impotence. JAMA 1993;270:83-90.
26. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998;159:1541-7.
27. Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra [registered trademark]). Urol 2006;68:26-37.
28. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O, Edwards D. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007;100:130-6.
29. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74.
30. Nicolosi A, Laumann EO, Glasser DB, Moreira J, Paik A, Gingell C. Sexual behavior and sexual dysfunctions after age 40: The global study of sexual attitudes and behaviors. Urology 2004;64:991-7.
31. Skoumal R, Chen J, Kula K, Breza J, Calomfirescu N, Basson BR, Kopernicky V. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004;46:362-9.
32. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O, Edwards D. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007
33. Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, Lang C, Horner R, Gutkin S, Dickson R. The treatment of erectile dysfunction study: Focus on treatment satisfaction of patients and partners. BJU Int 2007;99:376-82.
34. Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S. Therapeutic effectiveness and patient satisfaction after 6 months of Treatment with Tadalafil, Sildenafil, and Vardenafil: Results from the Erectile Dysfunction Observational Study (EDOS). Eur Urol 2007;51:541-50.
35. Sharlip ID, Shumaker BP, Hakim LS, Goldfischer E, Natanegara F, Wong DG. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in MEN over 65 years of age: Results from multiple observations in men with ED in National Tadalafil Study in the United States. J Sex Med 2008;5:716-25.
36. Wespes E, Moncada I, Schmitt H, Jungwirth A, Chan M, Varanese L. The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: Results of the SURE study. BJU Int 2007;99:121-6.
37. Carson C, Giuliano F, Goldstein I, Hatzichristou D, Hellstrom W, Lue T, Montorsi F, Munarriz R, Nehra A, Porst H, Rosen R. The "effectiveness" scale - Therapeutic outcome of pharmacologic therapies for ED: An international consensus panel report. Int J Impot Res 2004;16:207-13.
38. Montorsi F, Althof SE. Partner responses to sildenafil citrate (Viagra) treatment of erectile dysfunction. Urol 2004;63:762-7.
39. Lee J, Pommerville P, Brock G, Gagnon R, Pravinsagar M, Krisdaphongs M, Chan M, Chan J, Dickson R. Physician-rated patient preference and patient- and preference partner-rated for Tadalafil or Sildenafil citrate: Results from the Treatment of Erectile Dysfunction (TED) Canadian Observational Study. BJU Int 2006;98:623-9.
40. Conaglen HM, Conaglen JV. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: The partners' preference study. J Sex Med 2008;5:1198-207.